RxDoctor Payments DataLook up a doctor →

Samith Kochuparambil, MD

Hematology & Oncology · Minneapolis, MNNPI 1548490329

Payments from drug & device makers

$3,269,204in general payments, 2019–2025

Across 797 payments — averaging $4101.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1.7M
  • Merck$557K
  • Genentech, Inc.$503K
  • Mirati Therapeutics, Inc.$301K
  • EMD Serono, Inc.$97K
  • Janssen Research & Development, LLC$79K
  • plus $74K from 12 others

What the payments were for

  • Consulting fees$1,23856%
  • Speaking & faculty fees$73133%
  • Grants$1205%
  • Food & beverage$994%
  • Education$261%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,269,204 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,332,720
Medicare patients
366
Services billed
88,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate48$1,186,034
Lenalidomide39$481,178
XtandiEnzalutamide21$305,070
RevlimidLenalidomide16$258,474
BrukinsaZanubrutinib23$245,693
CalquenceAcalabrutinib Maleate19$217,820
TagrissoOsimertinib Mesylate13$210,600
RubracaRucaparib Camsylate12$150,083
GilotrifAfatinib Dimaleate12$133,542
Abiraterone Acetate86$97,066
VenclextaVenetoclax13$89,396
EliquisApixaban22$15,871
XareltoRivaroxaban13$7,203
Dexamethasone68$1,163
Hydroxyurea49$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$22,939$428,42032 claims
Beigene USA, Inc.Brukinsa$1,287$245,69323 claims
Clovis Oncology, Inc.Rubraca$5,096$150,08312 claims
AbbVieVenclexta$120$89,39613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.

Other hematology & oncology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →